Rekah Pharmaceutical Profit Margin vs. Total Debt

REKA Stock  ILA 1,392  9.00  0.64%   
Taking into consideration Rekah Pharmaceutical's profitability measurements, Rekah Pharmaceutical Industry may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Rekah Pharmaceutical's ability to earn profits and add value for shareholders.
For Rekah Pharmaceutical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Rekah Pharmaceutical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Rekah Pharmaceutical Industry utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Rekah Pharmaceutical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Rekah Pharmaceutical Industry over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center.
Please note, there is a significant difference between Rekah Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Rekah Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rekah Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Rekah Pharmaceutical Total Debt vs. Profit Margin Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Rekah Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Rekah Pharmaceutical value to that of its competitors to determine the firm's financial worth.
Rekah Pharmaceutical Industry is currently regarded as top stock in profit margin category among its peers. It also is currently regarded number one company in total debt category among its peers making up about  7,847,131,783  of Total Debt per Profit Margin. Comparative valuation analysis is a catch-all model that can be used if you cannot value Rekah Pharmaceutical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Rekah Pharmaceutical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Rekah Total Debt vs. Profit Margin

Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.

Rekah Pharmaceutical

Profit Margin

 = 

Net Income

Revenue

X

100

 = 
0.01 %
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Rekah Pharmaceutical

Total Debt

 = 

Bonds

+

Notes

 = 
101.23 M
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Rekah Total Debt vs Competition

Rekah Pharmaceutical Industry is currently regarded number one company in total debt category among its peers. Total debt of Health Care industry is at this time estimated at about 18.85 Billion. Rekah Pharmaceutical maintains roughly 101.23 Million in total debt contributing less than 1% to equities under Health Care industry.
Total debt  Capitalization  Valuation  Revenue  Workforce

Rekah Pharmaceutical Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Rekah Pharmaceutical, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Rekah Pharmaceutical will eventually generate negative long term returns. The profitability progress is the general direction of Rekah Pharmaceutical's change in net profit over the period of time. It can combine multiple indicators of Rekah Pharmaceutical, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company was founded in 1941 and is based in Holon, Israel. REKAH PHARMA operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 9 people.

Rekah Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Rekah Pharmaceutical. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Rekah Pharmaceutical position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Rekah Pharmaceutical's important profitability drivers and their relationship over time.

Use Rekah Pharmaceutical in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rekah Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rekah Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.

Rekah Pharmaceutical Pair Trading

Rekah Pharmaceutical Industry Pair Trading Analysis

The ability to find closely correlated positions to Rekah Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rekah Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rekah Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rekah Pharmaceutical Industry to buy it.
The correlation of Rekah Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rekah Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rekah Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Rekah Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Rekah Pharmaceutical position

In addition to having Rekah Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Electronics Thematic Idea Now

Electronics
Electronics Theme
Companies manufacturing electronic appliances and goods. The Electronics theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Electronics Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Rekah Stock

To fully project Rekah Pharmaceutical's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Rekah Pharmaceutical at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Rekah Pharmaceutical's income statement, its balance sheet, and the statement of cash flows.
Potential Rekah Pharmaceutical investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Rekah Pharmaceutical investors may work on each financial statement separately, they are all related. The changes in Rekah Pharmaceutical's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Rekah Pharmaceutical's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.